PMID: 9544383Apr 17, 1998Paper

Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL)

Australian and New Zealand Journal of Medicine
A J DavisS Milliken

Abstract

The development of non-Hodgkin's lymphoma (NHL) in AIDS conveys a poor prognosis with less than 10% of patients surviving beyond two years. These tumours are generally aggressive and often require systemic chemotherapy to bring about effective palliation. To report on the long term follow-up of patients with HIV related NHL treated with CEOP chemotherapy. This is a retrospective analysis of a group of 18 patients treated at two institutions between October 1990 and 1992 with modified CEOP chemotherapy. Doses were calculated using cyclophosphamide 750 mg/m2, epirubicin 50 mg/m2, vincristine 2 mg and prednisone 75-100 mg x five days, however initial doses of cyclophosphamide and epirubicin were modified to 50-75% of calculated dose. Seventeen of the 18 patients were male, one female; age range 26-79 (median 36 years); seven with immunoblastic, three Burkitt's, one Ki-1 (anaplastic), six diffuse large cell, and one mixed large and small cell. Eight patients (44%) achieved a complete remission, with seven patients (39%) achieving a partial remission, for an overall response rate of 83% (95% CI = 59-96%). Survival ranged from three-35 months (median nine months). Interestingly, four patients (22%) survived more than two years (media...Continue Reading

Citations

Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L RatnerUNKNOWN AIDS Malignancy Consortium

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.